PolyPid (PYPD) Total Liabilities (2019 - 2026)
PolyPid (PYPD) posted Total Liabilities of $19.2 million for Q1 2026, down 14.11% sequentially from $22.3 million in Q4 2025, and up 13.72% YoY from $16.8 million in Q1 2025.
PolyPid (PYPD) Total Liabilities (2019 - 2026) Analysis & Trends
PolyPid has reported Total Liabilities for 8 years, with the latest figure at $19.2 million in Q1 2026.
- Quarterly Total Liabilities rose 13.72% year-over-year to $19.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.2 million (up 13.72% YoY) and the FY2025 annual result came in at $22.3 million, down 11.55% from the prior year.
- Total Liabilities slipped to $19.2 million in Q1 2026 per PYPD's latest filing, from $22.3 million in the prior quarter.
- Over five years, Total Liabilities peaked at $37.7 million in Q2 2025 and troughed at $15.4 million in Q4 2023.
- A 5-year average of $25.4 million and a median of $25.4 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities plunged 49.2% in 2022, then surged 93.0% in 2025.
- Over 5 years, Total Liabilities stood at $26.0 million in 2022, then tumbled by 40.81% to $15.4 million in 2023, then jumped by 64.06% to $25.2 million in 2024, then retreated by 11.55% to $22.3 million in 2025, then decreased by 14.11% to $19.2 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $19.2 million, $22.3 million, and $26.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | PolyPid | 113.30 Mn | 106.53 Mn | - | 15.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.23 Mn |
| Mar 31, 2026 | 19.16 Mn |
| Dec 31, 2025 | 22.31 Mn |
| Sep 30, 2025 | 26.84 Mn |
| Jun 30, 2025 | 37.69 Mn |
| Mar 31, 2025 | 16.85 Mn |
| Dec 31, 2024 | 25.22 Mn |
| Sep 30, 2024 | 19.59 Mn |
| Jun 30, 2024 | 19.53 Mn |
| Mar 31, 2024 | 25.40 Mn |
| Dec 31, 2023 | 15.37 Mn |
| Sep 30, 2023 | 20.93 Mn |
| Jun 30, 2023 | 26.26 Mn |
| Mar 31, 2023 | 31.70 Mn |
| Dec 31, 2022 | 25.97 Mn |
| Sep 30, 2022 | 29.38 Mn |
| Jun 30, 2022 | 34.82 Mn |
| Mar 31, 2022 | 35.48 Mn |
| Dec 31, 2021 | 44.24 Mn |
| Sep 30, 2021 | 53.46 Mn |